Editorial: Prophylaxis in hbv-infected liver transplant patients: End of the HBIG era?

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 949-951

  Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; PHOSPHONIC ACID DERIVATIVE;

CHOLESTATIC HEPATITIS; COMBINATION CHEMOTHERAPY; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL; REINFECTION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; FEMALE; MALE; NOTE;

ADENINE; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; ORGANOPHOSPHONATES;

EID: 84878919919     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.122     Document Type: Review

References (15)

1. Kim W, Poterucha J, Kremers W et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004 ; 10 : 968-74. (Pubitemid 39232749)
2. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis aft er liver transplantation in HBsAg-positive patients. Lancet 1991 ; 337 : 813-5.
3. Perrillo R, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and aft er liver transplantation for chronic hepatitis B. Hepatology 2001 ; 33 : 424-32. (Pubitemid 32119032)
4. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis: a new strategy for prevention of reinfection in liver transplantation for hepatitis B DNA positive cirrhosis. Lancet 1996 ; 348 : 1212-5. (Pubitemid 26361609)
5. Fox AN, Terrault NA. Th e option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012 ; 56 : 1189-97.
6. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence aft er liver transplantation: a systematic review. Am J Transplant 2013 ; 13 : 353-62.
7. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 ; 329 : 1842-7. (Pubitemid 23360483)
8. Fung J, Chan S, Cheung C et al. Oral nucleoside/nucleotide analogues without hepatitis B immne globulin aft er liver transplantation. Am J Gastro enterol 2013 ; 108 : 942-8 (this issue).
9. Degertekin B, Han S, Keeff e E et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence aft er liver transplantation. Am J Transplant 2010 ; 10 : 1823-33.
10. Neff G, O ' brien C, Nery J et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004 ; 10 : 1372-8. (Pubitemid 39530052)
11. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 ; 132 : 931-7. (Pubitemid 46440868)
12. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003 ; 38 : 1419-27. (Pubitemid 37466968)
13. Fung J, Cheung C, Chan SC et al. Entecavir monotherapy is eff ective in suppressing hepatitis B virus aft er liver transplantation. Gastroenterology 2011 ; 141 : 1212-9.
14. Lenci I, Tisone G, Di Paolo D et al. Safety of complete and sustained prophylaxis withdrawal in patients liver transplanted for HBVrelated cirrhosis at low risk of HBV recurrence. J Hepatol 2011 ; 55 : 587-93.
15. Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011 ; 55 : 507-9.